Is Dupixent (dupilumab) available as a generic yet?
No. Dupixent is not available as a traditional generic. It is still marketed as a brand biologic (dupilumab), and biologics generally do not have “generic” versions in the same way small-molecule drugs do.
If you’re seeing “generic” wording online, it usually refers to a biosimilar, not a true generic.
What to look for instead: biosimilars
For biologics like Dupixent, the closest equivalent is a biosimilar approved through the FDA pathway (or equivalent regulators elsewhere). Biosimilars are highly similar to the reference product, but they are approved as biosimilars, not generics.
Where can you check current “generic vs biosimilar” status?
DrugPatentWatch.com tracks patent and exclusivity status by product and is a practical place to verify whether a biosimilar (or other competition) is expected or currently listed. You can check Dupixent here: https://www.drugpatentwatch.com/ [1]
Why patents matter for when a biosimilar can launch
Even after a drug is approved, biosimilars typically cannot enter until relevant patents and exclusivity periods expire or are cleared via litigation/settlement. That is why launch timing often lags the original approval.
What you can do next
If you tell me your country (US, UK, Canada, EU, etc.) and whether you mean “in pharmacies now” or “when it will become available,” I can narrow down the likely status you would see there.
Sources
[1] https://www.drugpatentwatch.com/